This excerpt taken from the SNTA 8-K filed Jun 19, 2009.
LEXINGTON, MA June 19, 2009 Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Vojo Vukovic, M.D., Ph.D. has been appointed Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. Prior to his appointment, Dr. Vukovic was Vice President, Clinical Research at Synta, a position he has held since January, 2009. Eric Jacobson, M.D., recently announced his resignation as Senior Vice President and Chief Medical Officer, and will be leaving Synta after a brief transition period.
Vojos experience in all stages of clinical development in a wide range of cancer indications will be invaluable to Synta as we advance STA-9090 in the clinic and as we complete our analyses for elesclomol, said Safi Bahcall, Ph.D., President and Chief Executive Officer, Synta. In addition to his clinical experience, Vojos research background in tumor biology will be an important advantage in advancing the translational science aspects of each of our programs. Vojo has demonstrated strong leadership working on our Hsp90 program to date, and I expect a smooth transition in his new role.
In addition to the on-going trials of STA-9090, Synta will be initiating a second, once-weekly dosing Phase 2 trial in hematologic cancers in the second half of the year, and expects to initiate several new Phase 2 clinical trials in solid tumors in 2009 and early 2010. More details regarding these trials will be announced later this year. Trials of elesclomol are currently on hold pending the completion of analyses of the results of the Phase 3 SYMMETRY trial in metastatic melanoma.
Dr. Bahcall thanked Dr. Jacobson for his contributions to Synta over the past four years. Eric has been a strong leader for our clinical team who has earned the respect and admiration of all of us at Synta as well as the many clinicians with whom he has worked on a variety of clinical trials in oncology and inflammatory disease. He will be missed by all of us at Synta and we wish him well in his future endeavors.
Dr. Vukovic joined Synta as Vice President, Clinical Research with 17 years experience in oncology drug development. Prior to Synta, he was Global Medical Lead for Sutent® and axitinib in a number of cancer indications at Pfizer. Prior to Pfizer, he served in key medical and regulatory roles at Aventis Pasteur, Ortho Biotech, ILEX Oncology, and BioNumerik Pharmaceuticals. Over the course of his career, Dr. Vukovic has been responsible for over 100 Phase 1 to Phase 4 clinical studies in cancer indications including melanoma, tumors of the lung, pancreas, breast, colorectal, ovarian, brain, as well as NHL and certain leukemias. Prior
to his industry career, Dr. Vukovic was a post-doctoral fellow at the Ontario Cancer Institute, Toronto in Ontario and Institute for Cell Biology in Essen, Germany where he conducted basic and translational research in solid tumor microenvironments and oxidative stress.
This excerpt taken from the SNTA 8-K filed Jun 15, 2009.
LEXINGTON, MA June 15, 2009 Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, announced today that GlaxoSmithKline (GSK) and Synta will end the collaborative agreement for the clinical development and commercialization of elesclomol effective no later than September 10, 2009. Worldwide rights to elesclomol will revert to Synta and Synta may pay GSK a low single-digit royalty on any potential future sales of elesclomol.
We appreciate GSKs contributions to this program and understand their decision, said Safi R. Bahcall, Ph.D., President and Chief Executive Officer of Synta. We will be meeting with medical and scientific advisors to review the data from the SYMMETRY trial and additional results later this year, and will use this guidance to inform our choices for a path forward for the program. We expect to report more on additional data and plans for the program later this year.
While we are continuing to evaluate the potential of elesclomol, we are focusing our resources on the other programs in our portfolio, particularly our Hsp90 program for which we expect to initiate a number of new clinical trials in the near term, continued Dr. Bahcall. With a strong cash position, a portfolio of first-in-class and best-in-class programs, and a productive discovery engine, we are excited about the potential of our pipeline and are committed to realizing the potential of these programs to benefit patients.
This excerpt taken from the SNTA 8-K filed Mar 26, 2009.
LEXINGTON, MA March 26, 2009 Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter and year ended December 31, 2008.
In the fourth quarter of 2008, the Company recorded $0.6 million of net collaboration revenues under its existing partnership agreement with GlaxoSmithKline (GSK) and its new partnership agreement with Hoffman-La Roche (Roche), which was entered into in December 2008. The Company reported a net loss attributable to common stockholders of $26.0 million or $0.77 per basic and diluted share for the fourth quarter in 2008, compared to a net loss of $15.5 million or $0.46 per basic and diluted share for the same period in 2007.
As of December 31, 2008, the Company had $89.6 million in cash, cash equivalents, marketable securities and collaboration payments receivable, which includes the $16 million non-refundable upfront payment that was paid in January 2009 under the agreement with Roche. This compares to $115.6 million in cash, cash equivalents and marketable securities as of December 31, 2007. There were no collaboration payments receivable as of December 31, 2007.
In the first quarter of 2009, the Company achieved and was paid a $10 million non-refundable operational milestone payment under the GSK Agreement related to the development of elesclomol for the treatment of metastatic melanoma. This payment is not included in the above total.